Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Meibomian Gland Dysfunction Market Forecast: What Value Will The Market Reach By 2030?
The meibomian gland dysfunction market has experienced substantial growth in recent times. This market is projected to expand from $4.42 billion in 2025 to $4.73 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 7.0%. Historically, this expansion has been driven by factors such as a rise in dry eye disease incidence, increased screen time exposure, the growing aging population, wider clinical recognition of mgd, and the availability of basic treatment options.
The meibomian gland dysfunction market size is anticipated to undergo significant growth over the next few years. It is projected to expand to $6.12 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.6%. This increase during the forecast period is attributable to factors such as the increasing adoption of device-assisted therapies, rising investments in ophthalmic care, a growing awareness of chronic eye conditions, the expansion of home-use treatment devices, and an increasing focus on personalized eye care. Key trends in this period are expected to include the increasing adoption of advanced diagnostic tools, a rising utilization of device-based therapies, a growing preference for combination treatment approaches, the expansion of home-based management solutions, and an enhanced focus on early disease detection.
Get A Free Sample Report With In-Depth Market Insights:
Meibomian Gland Dysfunction Market Demand Drivers: What’s Powering Industry Growth?
The meibomian gland dysfunction (MGD) market is anticipated to expand, driven by the increasing incidence of eye disease. Eye disease refers to any condition or disorder affecting the eye or visual system, compromising its structure, function, or overall health. The growing number of eye disease cases is attributed to increased screen time and digital eye strain, leading to symptoms such as dryness, blurred vision, and long-term retinal damage from extended blue light exposure. Meibomian gland dysfunction exacerbates eye disease by destabilizing the tear film, which results in inflammation, dryness, and an elevated risk of ocular surface disorders. For instance, in February 2025, the National Institutes of Health (NIH), a US-based government agency, reported that the global prevalence of myopia is projected to increase to 36.59% by 2040 and 39.80% by 2050, with the total number of cases expected to exceed 740 million by 2050. Thus, the rising occurrences of eye disease are a primary driver for the growth of the meibomian gland dysfunction (MGD) market.
Meibomian Gland Dysfunction Market Segment Analysis And Revenue Potential
The meibomian gland dysfunction market covered in this report is segmented –
1) By Treatment Type: Medication, Surgery, Lifestyle Modifications
2) By Dysfunction Type: Obstructive Meibomian Gland Dysfunction, Evaporative Meibomian Gland Dysfunction, Mixed Meibomian Gland Dysfunction
3) By Disease Severity: Mild Meibomian Gland Dysfunction, Moderate Meibomian Gland Dysfunction, Severe Meibomian Gland Dysfunction
4) By Distribution channel: Hospitals And Clinics, Pharmacies, Online Retailers
5) By End-User: Hospitals, Ophthalmology Clinics, Home Care Settings
Subsegments:
1) By Medication: Topical Antibiotics, Topical Steroids, Lubricating Eye Drops, Topical Cyclosporine, Omega-3 Supplements
2) By Surgery: Meibomian Gland Probing, Intense Pulsed Light (IPL) Therapy, Thermal Pulsation Treatment, BlephEx
3) By Lifestyle Modifications: Warm Compress Therapy, Lid Hygiene, Dietary Adjustments, Blinking Exercises
Meibomian Gland Dysfunction Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies active in the meibomian gland dysfunction market are prioritizing the creation of novel treatments, such as prescription eye drop solutions, to diminish tear evaporation and alleviate dry eye discomfort. These prescription eye drop solutions, including anti-inflammatory or antibiotic varieties, contribute to managing meibomian gland dysfunction by reducing inflammation, clearing gland obstructions, and enhancing tear film stability. For example, in May 2023, Bausch + Lomb Corporation, an eye health company from Canada, unveiled MIEBO (perfluorohexyloctane ophthalmic solution), an innovative prescription eye drop developed for the treatment of dry eye disease (DED). As the initial and sole prescription eye drop engineered to directly tackle tear evaporation, which is the main cause of DED, MIEBO creates a protective, enduring layer over the ocular surface. Its advanced water-free formulation delivers effective and sustained relief, particularly benefiting patients experiencing dry eye symptoms linked to Meibomian gland dysfunction.
Meibomian Gland Dysfunction Market Key Players Shaping Industry Direction
Major companies operating in the meibomian gland dysfunction market are Johnson And Johnson, Alcon Inc., Bausch Lomb Corporation, Santen Pharmaceutical, Lumenis Ltd, Topcon Healthcare Solutions Inc, AFT Pharmaceuticals, Sight Sciences Inc, OASIS Medical Inc, OCuSOFT Inc, Novaliq GmbH, Scope Ophthalmics Ltd, Medmont International Pty Ltd, Azura Ophthalmics Ltd, BlephEx LLC, Bruder Healthcare Company, ESW Vision Inc, MiBo Medical Group Inc, Kala Pharmaceuticals Inc, Allergan Eye Care, TearScience Inc, Sun Pharmaceutical Industries Ltd
View The Full Meibomian Gland Dysfunction Market Report:
Meibomian Gland Dysfunction Market Top Region By Revenue And Market Share
North America was the largest region in the meibomian gland dysfunction market in 2025. The regions covered in the meibomian gland dysfunction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
